TECHNICAL TREND ( NIFTY - BANK NIFTY FUTURES )

NIFTY FIFTY : - Nifty futures and bank nifty future market closed at 10291/ 25365,.according to
technical analysis if nifty futures and bank nifty future moves upward direction in upcoming treading
sessions then 10400/ 24500 will be next resistance level, if it break this level then nifty futures and
bank nifty future can touch 10500 / 26000 level . meanwhile in reveres there is support on
10200/25200 for nifty futures and bank nifty future after breaking this support with volume there is
big support for nifty futures and bank nifty future on 10000/24800.

Monday, 11 Dec 2017

TECHNICAL VIEW (NIFTY- BANK NIFTY FUTURES )

NIFTY

DAILY R2 R1 PP S1 S2
10528 10354 10266 10180 10006

WEEKLY R2 R1 PP S1 S2
10950 10460 10215 9968 9478

MONTHLY R2 R1 PP S1 S2
11510 107000 10295 9891 9081

BANK NIFTY

DAILY R2 R1 PP S1 S2
25800 25486 25328 25171 24856

WEEKLY R2 R1 PP S1 S2
26725 25718 25214 24709 23701

MONTHLY R2 R1 PP S1 S2
28596 26583 25575 24569 22555

MOVING AVERAGE 21 DAYS 50 DAYS 100 DAYS 200 DAYS

NIFTY 10274 10240 10102 9738

BANK NIFTY 25528 25075 24794 23585

PARABOLIC SAR DAILY WEEKLY MONTHLY

NIFTY 10494 9131 7674

BANK NIFTY 24801 21325 16225

PATTERN FORMATION ( NIFTY )

Details of Chart - Last week nifty opened at 10167and close at 10292 made high of 10298 and
low of 10052,moved almost 240 point in upward direction. according to technical analysis if nifty
can move further in upward direction then 10400 will be next resistance level of nifty if it can
break this level then further can go in it lifetime high..
PATTERN FORMATION ( BANK NIFTY )

Detail of Chart - Last week banknifty opened at 25300 and close at 25365 made high of25390
and low of 24885 shows its consolidate movement acording to technical analysis if bank nifty can
sustain the level of 25300 can show its upward movement can go upto 25600,next major resistance
for bank nifty is 25600. if bank nifty can break this level can go upto 26000.
NSE EQUITY DAILY LEVELS

COMPANY R3 R2 R1 PP S1 S2 S3
ADANIPORTS EQ 428.05 408.50 400.55 388.95 381.00 369.40 349.85
NAME
AMBUJACEM EQ 292.75 279.00 274.25 265.25 260.50 251.50 237.75
ASIANPAINT EQ 1238.35 1183.85 1159.70 1129.35 1105.20 1074.85 1020.35
AUROPHARMA EQ 732.35 700.35 686.70 668.35 654.70 636.35 604.35
AXISBANK EQ 569.65 554.35 548.90 539.05 533.60 523.75 508.45
BAJAJ-AUTO EQ 3476.90 3332.55 3273.75 3188.20 3129.40 3043.85 2899.50
BAJFINANCE EQ 1822.90 1759.95 1732.95 1697.00 1670.00 1634.05 1571.10
BHARTIARTL EQ 618.50 564.50 544.15 510.50 490.15 456.50 402.50
BOSCHLTD EQ 22331.00 21019.95 20330.00 19708.90 19018.95 18397.85 17086.80
BPCL EQ 559.55 533.00 523.55 506.45 497.00 479.90 453.35
CIPLA EQ 636.65 618.45 611.70 600.25 593.50 582.05 563.85
COALINDIA EQ 289.35 278.10 271.35 266.85 260.10 255.60 244.35
DRREDDY EQ 2404.90 2309.25 2247.85 2213.60 2152.20 2117.95 2022.30
EICHERMOT EQ 32283.45 30636.55 29868.30 28989.65 28221.40 27342.75 25695.85
GAIL EQ 578.10 528.00 506.00 477.90 455.90 427.80 377.70
HCLTECH EQ 952.10 904.15 887.55 856.20 839.60 808.25 760.30
HDFC EQ 1769.70 1720.55 1701.95 1671.40 1652.80 1622.25 1573.10
HDFCBANK EQ 1943.85 1887.95 1865.10 1832.05 1809.20 1776.15 1720.25
HEROMOTOC EQ 3866.75 3705.10 3613.55 3543.45 3451.90 3381.80 3220.15
HINDALCO
O EQ 263.30 250.55 244.40 237.80 231.65 225.05 212.30
HINDPETRO EQ 479.35 449.35 438.70 419.35 408.70 389.35 359.35
HINDUNILVR EQ 1476.35 1386.55 1352.30 1296.75 1262.50 1206.95 1117.15
IBULHSGFIN EQ 1304.35 1246.35 1225.70 1188.35 1167.70 1130.35 1072.35
ICICIBANK EQ 334.45 320.70 315.75 306.95 302.00 293.20 279.45
INDUSINDBK EQ 1747.70 1708.00 1690.50 1668.30 1650.80 1628.60 1588.90
INFRATEL EQ 420.10 398.15 385.90 376.20 363.95 354.25 332.30
INFY EQ 1068.55 1030.10 1014.75 991.65 976.30 953.20 914.75
IOC EQ 447.70 422.90 414.20 398.10 389.40 373.30 348.50
ITC EQ 283.55 271.20 266.85 258.85 254.50 246.50 234.15
KOTAKBANK EQ 1043.95 1024.45 1017.40 1004.95 997.90 985.45 965.95
LT EQ 1287.75 1249.75 1234.50 1211.75 1196.50 1173.75 1135.75
LUPIN EQ 865.15 842.40 833.05 819.65 810.30 796.90 774.15
M&M EQ 1503.25 1446.70 1416.85 1390.15 1360.30 1333.60 1277.05
MARUTI EQ 10215.90 9546.95 9305.95 8878.00 8637.00 8209.05 7540.10
NTPC EQ 194.60 187.05 184.30 179.50 176.75 171.95 164.40
ONGC EQ 197.00 188.60 185.00 180.20 176.60 171.80 163.40
POWERGRID EQ 215.55 208.45 205.85 201.35 198.75 194.25 187.15
RELIANCE EQ 1000.90 959.40 940.35 917.90 898.85 876.40 834.90
SBIN EQ 338.05 326.15 319.70 314.25 307.80 302.35 290.45
SUNPHARMA EQ 560.70 541.00 532.50 521.30 512.80 501.60 481.90
TATAMOTORS EQ 444.05 425.30 418.10 406.55 399.35 387.80 369.05
TATASTEEL EQ 795.85 742.70 718.40 689.55 665.25 636.40 583.25
TCS EQ 2741.50 2680.00 2640.00 2618.50 2578.50 2557.00 2495.50
TECHM EQ 559.95 523.05 509.65 486.15 472.75 449.25 412.35
ULTRACEMCO EQ 4485.75 4304.35 4229.55 4122.95 4048.15 3941.55 3760.15
UPL EQ 820.85 768.70 748.45 716.55 696.30 664.40 612.25
VEDL EQ 325.70 306.90 298.55 288.10 279.75 269.30 250.50
WIPRO EQ 305.75 295.25 288.90 284.75 278.40 274.25 263.75
YESBANK EQ 339.35 324.45 318.50 309.55 303.60 294.65 279.75
ZEEL EQ 616.80 591.10 577.60 565.40 551.90 539.70 514.00
 TOP 15 ACHIEVERS // TOP 15 LOOSERS

SR.NO SCRIPT NAME PREV CMP % SR.NO SCRIPT NAME PREV CMP % CHANGE
CLOSE CHANGE CLOSE

1 484.30 533.15 +10.9 1 LAKVILA BANK 171.25 149.50 -12.70

BHARTI AIRTEL
2 8500.80 9118.95 +7.27 2 TEX MOPIPE PR 32.25 29 -10.36
MARUTI SUZUKI
3 472.80 497.45 +5.21 3 L&T TECH 1105.20 1005.05 -9.06
TECH MAH LTD
4 496.20 520.75 +4.95 4 APEX FRO FO 818.25 772.75 -5.56
BHARAT PETRO
5 412.40 431.30 +4.58 5 GITANJ GEMS 80.75 76.35 -5.45
HIND PETROL
6 255.10 266.45 +4.45 6 RUPA & COM 479.05 453.95 -5.25
ITC LTD
7 1268.60 1323.50 +4.33 7 IRB INFRA 213.65 203.60 -4.70
HINDU UNILEVER
8 390.55 406.45 +4.07 8 JUBIL FO WORK 1732.30 1676.05 -3.25
INDIA OIL CORPO.
9 463.15 479.35 +3.50 9 FO HEALTCARE 148.35 143.55 -3.24
GAIL( INDIA ) LTD
10 261.10 270.25 +3.50 10 JINDAL STL 106.90 103.50 -3.18
AMBUJA CEMENT
11 847.95 876 +3.31 11 NITCO LTD 109.55 106.10 -3.15
HCL TECHNOLOGI
12 303.20 312.75 +3.15 12 JINDAL & PWR 169.25 164 -3.10
YES BANK
13 711.05 732 +2.95 13 HCL INF SYS 52.25 50.65 -3.06
UPL
14 814.45 836.80 +2.74 14 HINDZINC 299.70 292.40 -2.44
LUPIN LTD
15 4110.05 4220.05 +2.68 15 HEROMOTOCO 3601.40 3522.35 -2.19
ULTRA TECH CEM

AM 204 232 +13.67 AMBUJA CEMENT

BUJ %
A
CEM
ENT
NEXT WEEK STARS (AS PER TECHNICAL ANALYSIS)

NSE FUTURE

NSE FUTURE : BUY INDUSIND BANK FUTURE ABOVE 1700 TGT 1750 SL 1680

NSE FUTURE : SELL GAIL FUTURE BELOW 480 TGT 475 SL 484

NSE CASH

NSE CASH : BUY AUBANBK CASH ABOVE 720 TGT 760 SL 700

NSE CASH : BUY MUTHOOT FINANCE IN NSE CASH ABOVE 447 TGT 492 SL 430
NSE - WEEKLY NEWS LETTERS

TOP NEWS OF THE WEEK

Next week once again promises to be full of action as a slew of macro-economic data are
scheduled to be announced.The October Industrial production data will be released on
December 12 and December 14 will see the Wholesale price inflation data for the month of
November released.Apart from domestic data all eyes will also be on the FED interest rate
decision.

Upcoming events

DEC 12 OCT IIP YOY

DEC 13 FED INTEREST RATE DECISION

DEC 14 NOV WPI INFLATION YOY

RBI KEEPS THE REPO RATE UNCHANGED AT 6% - On the basis of an assessment

by Monetary Policy Committee decided to keep the policy repo rate under the liquidity
adjustment facility unchanged at 6%.Consequently, the reverse repo rate under the LAF
remains at 5.75%, and the marginal standing facility rate and the Bank Rate at 6.25%.The
decision of the MPC is consistent with a neutral stance of monetary policy in consonance with
the objective of achieving the medium-term target for consumer price index inflation of
4% within a band of +/- 2% while supporting growth.The decision was executed with a
majority vote of 5 out of 6 in favor of the monetary policy decision.
RBI'S NEUTRAL STANCE IN CONSONANCE WITH MEDIUM-TERM CPI
INFLATION TARGET OF 4% - On the basis of an assessment of the current and
evolving macroeconomic situation the Monetary Policy Committee decided to keep the policy
repo rate under the liquidity adjustment facility unchanged at 6.0%. The decision of the MPC
is consistent with a neutral stance of monetary policy in consonance with the objective of
achieving the medium-term target for consumer price index inflation of 4%.The headline
inflation outcomes have evolved broadly in line with projections. RBI mentioned that going
forward, inflation should be influenced by several factors:

The moderation in inflation excluding the food and fuel observed in Q1FY17-18 has by and
arge reversed and there the upward trajectory may continue;

Impact of HRA by the central government is expected to peak in December and the staggered
impact of increase in HRA by various state government may further push up the housing
inflation;

The recent rise in international crude oil prices may sustain and in such a scenario, any adverse
supply shock due to geopolitical developments could push up prices even further.

In addition to the above some seasonal moderation in vegetable prices is expected in the near
term. Also, the GST council in its last meeting has brought several retail goods and services to
lower tax brackets, which should translate into lower retail prices, going forward.

BHEL BAGS RS215CR R&M ORDER FROM BIHAR POWER PLANT - Bharat Heavy
Electricals Limited has secured an order for Electrostatic Precipitators at NTPC's Kahalgaon
Super Thermal Power Station in Bihar. The turnkey order includes carrying out R&M of the
ESPs originally supplied by BHEL. These ESPs have been operating successfully for more
than 25 years since the commissioning of the plant. BHEL's scope of work in the contract
includes design, engineering, manufacture, supply, dismantling, erection, testing and
commissioning of the ESPs to bring down the suspended particulate matter emission to the
recommended level for all the four units of this STPS.
With this order, BHEL has consolidated itself as the market leader in ESPs. BHEL is already
executing similar R&M projects for NTPC and state utilities like GSECL, CSPGCL, etc.
BHELs order book at the end of September 2017 stood at Rs97,000cr , while order inflows
came in at Rs1,870cr in Q2FY18. The stock trades at~22xFY19E EPS. As per media reports,
BHEL is also well placed on Rs5,000cr, 800 MW EPC order from Singaneri Collieries,
Telangana.

TVS MOTOR ACQUIRES 15% STAKE IN ELECTRIC TWO-WHEELER STARTUP

ULTRAVIOLETTE FOR RS.5CR - TVS Motor bought 14.78% stake in Ultraviolette
Automotive Pvt. Ltd, a Bengaluru-based startup working on electric two-wheelers and energy
infrastructure, for Rs5cr. Ultraviolette Automotive was incorporated in December 2015 and
has reported Rs3.2lakh revenue for FY17. It has tested three prototypes, however, has not
launched an electric two-wheeler yet. Additionally, TVS is developing an electric scooter
code-named U218 in order to compete in the category with players like Bajaj Auto Ltd, Honda
Motorcycle and Scooter India Pvt. Ltd, Mahindra 2 Wheelers Ltd and India Yamaha Motor
Pvt. Ltd, which are all set to launch electric two-wheelers in 2018, as per the media reports.
This acquisition would provide the expertise exposure in the electric two-wheeler segment.

DEEPAK NITRITE PLANS TO RAISE FUNDS VIA QIP - Deepak Nitrite is planning to
raise funds through Qualified Institutions Placement of equity shares of the company. The
meeting of Board of Directors of the company is scheduled to be held on December 11, 2017,
to consider the same. This fundraising is to finance its capex plans for its high margin projects,
which would improve its revenues and margins going ahead. The company had already raised
Rs150cr via a Qualified Institutional Placement in March 2017. Out of the net proceeds, the
company has invested Rs 64 cr towards the phenol project. DNL is well-positioned to drive
strong earnings growth in quarters to come, driven by
1) Commissioning of the phenol-acetone plant
2) Volume growth and margin expansion in fine and specialty chemicals
3) Turnaround in the performance products segment
4) Tailwinds for the basic chemicals segment from stricter environmental norms in China.
DELHI GOVERNMENT CANCELS LICENSE OF MAX HOSPITALS SHALIMAR
BAGH - Max India Ltd equal joint venture with Life Healthcare, Max Healthcare Institute
Ltd has received a notice of cancellation of the license of one of its hospitals at Shalimar Bagh,
New Delhi from Government of NCT of India. The license cancellation order was imposed
after a premature baby was wrongly declared dead last week.

A panel formed by the Delhi government to look into the case found the hospital
administration guilty of not following prescribed medical norms in dealing with newborn
infants. Max Healthcare Institute Ltd, through its press release, has expressed that the ruling is
harsh and no adequate opportunity to be heard has been given by the government. The
company also mentioned in the press release that even if there is an individual error of
judgement, holding the hospital responsible is unfair and will severely limit the ability for
patients to access treatment. This will compound the shortage of hospital facilities in the
National Capital.

IRB INFRA DOWN 3.9% AFTER CBI FILES CHARGESHEET - IRB Infrastructure
Developers Ltd disclosed that its subsidiary Aryan Infrastructure Investments Private Limited
along with certain other persons have been charge-sheeted by the CBI in the matter of an
illegal purchase of government land. AIIPL had begun purchasing land parcels in 2007 and
eventually acquired 1200 acres of land. In early 2009, AIIPL observed that ~5% of the land
was owned by the Maharashtra State Road Development Corporation. After this observation,
AIIPL canceled the land sale agreements for these land parcels. The company believes that this
development should not have a material impact on the business or operations of the company.

GAIL AWARDS CONTRACT FOR LAYING 520KM PIPELINE NETWORK - GAIL

India announced that it had awarded contracts for a 520-km pipeline under the Pradhan Mantri
Urja Ganga gas pipeline project. With the awarding of these major contracts, phase-II of the
Jagdishpur-Haldia and Bokaro-Dhamra Natural Gas Pipeline project has been finalised. The
2,655-km long JHBDPL project, also known as the 'Pradhan Mantri Urja Ganga' project, will
pass through Uttar Pradesh, Bihar, Jharkhand, West Bengal and Odisha. The project will cater
to the demands of industrial users like fertilizer plants, power generation plants, refineries,
steel plants and other power intensive industries.
GAIL also stated that city gas network laying activity in Varanasi and Bhubaneswar has
already begun. Laying of city gas network will begin in Patna, Ranchi, Jamshedpur, Cuttack
and Kolkata by next month. GAIL announced a capex commitment of Rs6,000cr for FY18, an
increase of 50% from last years capex. These are long term positive developments for the
stock and should have a positive effect on the price. GAILs revenue from various segments
for FY17 stood at 71% gas marketing, 10% gas transmission and 19% from others.

NEW INDIA ASSURANCE BAGS RAJASTHAN HEALTH INSURANCE PROJECT-

New India Assurance Company Limited has announced that it will execute health insurance for
about one crore poor families across the State. Under the project called the Bhamasha
Swasthya Bima Yojana, about four crore people covered under the National Food Security Act
will get health insurance benefits. This is one of the largest health insurance schemes in the
country, as it gives cover for cashless treatment of 1,401 diseases - of Rs 3,00,000 for 663
critical and Rs 30,000 each for 738 general illnesses. G Srinivasan, Chairman and MD, NIA
said, This is one of the unique universal health insurance schemes in the country and the
scheme is operated through a large number of empanelled hospitals both public and private .
The total insurance premium involved is more than Rs1,200cr per annum with the State
bearing Rs1,261 per family. The basic aims of the Bhamashah Swasthya Bima Yojana is
improvement in health indicators, reduction in out of pocket expenses and providing financial
security to the poor against illnesses, to roll out Governments vision of maximum Governance
and minimum Government and bring a revolution in healthcare in rural area by providing
stimulus to Private Sector to open hospitals in rural areas and reducing the increasing burden
on Government facilities. NIA is the largest general insurance company in India in terms of net
worth, domestic gross direct premium, profit after tax and number of branches.

The company has been in operation for almost a century. NIA has the largest market share of
gross direct premium among general insurers in India NIAs operations are spread across 29
States and seven Union Territories in India and across 28 other countries globally through a
number of international branches, agency offices and subsidiaries including a desk at Lloyds,
London.
The Gross Written Premium for the half year ended September 30, 2017, was Rs12,823.49cr as
against a figure of Rs11,203.62cr in the previous year, registering a growth of 14.46%. The
Return on Equity of the company for the first half was 19.98% as compared to 8.52% during
the same period the previous year. The Solvency margin as on September 30, 2017 was very
comfortable at 2.24x as compared to 2.04x of the earlier year.

CADILA HEALTHCARES ARM RECEIVES FINAL APPROVAL FROM USFDA FOR

CLOZAPINE TABLETS - Cadila Healthcares wholly owned subsidiary - Zydus
Pharmaceuticals Inc., has received the final approval from the US Food and Drug
Administration to market Clozapine Tablets in strengths of 25 mg, 50 mg, 100 mg, and 200
mg. The drug is used to treat schizophrenia. It will be manufactured at the groups
formulations manufacturing facility at SEZ, Ahmedabad. The stock to react positively on this
news, as it will consolidate Cadilas position in the US generic market and improve its US
Sales.The company now has more than 175 approvals and has so far filed over 310 ANDAs
since the commencement of the filing process in FY 2003-04.

SHAREHOLDERS OF AXIS BANK APPROVE THE BOARDS CAPITAL RAISING

PLAN OF RS11,626CR - The shareholders of Axis Bank Ltd approved capital raising plan
proposed by the board on December 8, 2017.The proposal by the board of directors of the bank
was to raise equity and equity-linked capital of Rs11,626cr from a set of marquee investors
including entities affiliated with Bain Capital Private Equity, other investors advised by
Capital Research and the banks promoter, Life Insurance Corporation of India.The bank has
received approval for the capital raising plan from the board of directors on November 10,
2017.Axis Bank is the third largest private bank in India in terms of the loan book. It retains a
strong market position in corporate lending due to its superior banking channels and debt
capital service capabilities.Its loan mix as on FY17 consisted of corporate, retail segment and
SMEs, contributing 45%, 42%, and 13% respectively. Also, its FY17 GNPA's and NNPA's
stood at 5.5% and 2.3% respectively.
ULTRATECH TO SETUP 3.5 MTPA INTEGRATED UNIT IN PALI, RAJASTHAN -
UltraTech Cement has approved the setting up of a 3.5 MTPA integrated unit at Pali,
Rajasthan. The plant is expected to get commissioned by June 2020 with a total capital
expenditure of Rs1,850cr. This move has come up in order to cater to the western Rajasthan
where the company does not have a significant presence. In addition, the board of UltraTech
also approved the increase in the investment limit by Registered Foreign Portfolio Investors,
including FII, from the existing limit of 30% of the paid-up equity share capital of the
company to 40%, subject to shareholders approval

UCL is the largest pan India cement company with a capacity of 89 MTPA. UCL enjoys a
premium position in the most markets it operates. UCLs cement capacity increased from 22
MTPA to 49 MTPA in July 2010 following a merger with standalone cement business of
Grasim Industries. In FY18, UCLs capacity further increased by ~25% through the acquisition
of 21.2mtpa capacity of JPA. In addition, the company has 80% stake in Dubai based Star
Cement, 0.5 MTPA cement grinding capacity in Bangladesh, and 0.4mtpa cement grinding
capacity in Bahrain. In the last trading session.

GLENMARK PHARMA ANNOUNCES DOSING OF FIRST PATIENT WITH

INVESTIGATIONAL IMMUNO-ONCOLOGY AGENT - Glenmark Pharmaceuticals
announced that the first patient has been dosed in a Phase 1 trial of GBR 1342
(NCT03309111), an investigational bispecific antibody. This first-in-human, open-label studys
primary objective is to assess the safety and tolerability of increasing doses of GBR 1342 in
multiple myeloma patients until a maximum tolerated dose is reached. This trial is a step in a
right direction as it will strengthen its higher-margin biologics pipeline with lesser
competition. Three of the companys biologics, two of which are immuno-oncology agents,
have begun clinical trials. Glenmarks immuno-oncology pipeline currently includes three
candidates being studied in a wide range of tumor types. It has a diverse pipeline with several
compounds in various stages of clinical development, primarily focused in the areas of
immuno-oncology, respiratory disease and dermatology. The company is also pursuing
partnership opportunities for four of its novel molecules & expects to out-license at least one
of them in FY18E. This may help in debt reduction.
LEGAL DISCLAIMER

This Document has been prepared by Ways2Capital (A Division of High Brow Market Research
Investment Advisor Pvt Ltd). The information, analysis and estimates contained herein are based on
Ways2Capital Equity/Commodities Research assessment and have been obtained from sources
believed to be reliable. This document is meant for the use of the intended recipient only.

This document, at best, represents Ways2Capital Equity/Commodities Research opinion and is meant
for general information only. Ways2Capital Equity/Commodities Research, its directors, officers or
employees shall not in any way to be responsible for the contents stated herein. Ways2Capital
Equity/Commodities Research expressly disclaims any and all liabilities that may arise from
information, errors or omissions in this connection. This document is not to be considered as an offer
to sell or a solicitation to buy any securities or commodities.

All information, levels & recommendations provided above are given on the basis of technical &
fundamental research done by the panel of expert of Ways2Capital but we do not accept any liability
for errors of opinion. People surfing through the website have right to opt the product services of their
own choices.
Any investment in commodity market bears risk, company will not be liable for any loss done on
these recommendations. These levels do not necessarily indicate future price moment. Company holds
the right to alter the information without any further notice. Any browsing through website means
acceptance of disclaimer.

DISCLOSURE
High Brow Market Research Investment Advisor Pvt. Ltd. or its associates does not do business with
companies covered in research report nor is associated in any manner with any issuer of products/
securities, this ensures that there is no actual or potential conflicts of interest. To ensure compliance
with the regulatory body, we have resolved that the company and all its representatives will not make
any trades in the market.
Clients are advised to consider information provided in the report as opinion only & make investment
decision of their own. Clients are also advised to read & understand terms & conditions of services
published on website. No litigations have been filed against the company since the incorporation of
the company.

Disclosure Appendix:
The reports are prepared by analysts who are employed by High Brow Market Research Investment
Advisor Pvt. Ltd. All the views expressed in this report herein accurately reflects personal views about
the subject company or companies & their securities and no part of compensation was, is or will be
directly or indirectly related to the specific recommendations or views contained in this research
report.

Disclosure in terms of Conflict of Interest:

(a) High Brow Market Research Pvt. Ltd. or his associate or his relative has no financial interest in the
subject company and the nature of such financial interest;
(b) High Brow Market Research Pvt. Ltd. or its associates or relatives, have no actual/beneficial
ownership of one percent or more in the securities of the subject company,
(c) High Brow Market Research Pvt. Ltd. or its associate has no other material conflict of interest at
the time of publication of the research report or at the time of public appearance;
Disclosure in terms of Compensation:
High Brow Market Research Investment Advisor Pvt. Ltd. policy prohibits its analysts, professionals
reporting to analysts from owning securities of any company in the analyst's area of coverage.
Analyst compensation: Analysts are salary based permanent employees of High Brow Market
Research Pvt. Ltd.

Disclosure in terms of Public Appearance:

(a) High Brow Market Research Pvt. Ltd. or its associates have not received any compensation from
the subject company in the past twelve months;
(b) The subject company is not now or never a client during twelve months preceding the date of
distribution of the research report.
(c) High Brow Market Research Pvt. Ltd. or its associates has never served as an officer, director or
employee of the subject company;
(d) High Brow Market Research Pvt. Ltd. has never been engaged in market making activity for the
subject company.